You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back


Amoxil - European Harmonisation process

On 25 June 2015, the European Medicines Agency completed a review of Amoxil. The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that there was a need to harmonise the prescribing information for Amoxil in the European Union (EU).

Please note that the Amoxil SPCs and PILs were updated on 2nd March 2016 in line with this European Harmonisation process. Please follow the links below for further information.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.

Amoxil is a registered trademark of the GlaxoSmithKline Group of Companies